Receptor tyrosine-protein kinase erbB-2 extracellular domain (HER2 ECD)

The HER2 extracellular domain is the region of the receptor tyrosine-protein kinase erbB-2 that projects outside the cell membrane. It consists of four subdomains (I–IV) and mediates receptor dimerization, especially with other EGFR family members (EGFR, HER3, HER4). Unlike other EGFR family proteins, HER2 does not bind a soluble ligand directly but acts as a preferred dimerization partner, activating downstream signaling pathways (MAPK, PI3K/AKT, STAT) that regulate cell proliferation and survival[1][2][3][6][7][8]. Overexpression or mutation of HER2 ECD is implicated in aggressive cancers, notably breast cancer, where it drives ligand-independent signaling and resistance to apoptosis. This domain is the primary target of clinically approved monoclonal antibodies such as trastuzumab and pertuzumab, which bind to distinct regions within the ECD to inhibit oncogenic activity by blocking dimerization and inducing immune-mediated cell death[5][7]. The structural rigidity, absence of ligand binding, and propensity for activating mutations make HER2 ECD a unique and important drug target, but therapeutic challenges include cardiotoxicity and resistance mechanisms[1][4][5][7]. The HER2 ECD's role as a biomarker is established in oncology for patient stratification and disease monitoring, and its molecular structure continues to guide new drug development in cancer therapeutics.

Other names

HER2 extracellular domainERBB2 extracellular domainHER2/neu extracellular domainErbB-2 ECD

Monoclonal antibody binding to ECD inhibits dimerization and signal transduction. Antibody-dependent cellular cytotoxicity (ADCC). Prevention of ligand-independent activation. Downregulation of HER2 expression and internalization.[4][5][7]